This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Edwards Lifesciences Presents Positive Partner 3 Trial Data
by Zacks Equity Research
Edwards Lifesciences (EW) expects SAPIEN 3 to gain FDA approval for the low-risk indication in late-2019.
Medtronic (MDT) Releases Encouraging Evalut TAVR Result
by Zacks Equity Research
Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.
Boston Scientific (BSX) Rides on Acquisitions, Innovation
by Zacks Equity Research
Boston Scientific (BSX) takes a big leap forward by closing the buyout of Millipede and inking a deal to purchase BTG plc.
Boston Scientific's EP Arm Gets a Lift From Study Success
by Zacks Equity Research
The positive result regarding Boston Scientific's (BSX) LUMINIZE RF Balloon Catheter is expected to help the company further advance with the procedures to clinch a CE Mark for the instrument.
Boston Scientific's WATCHMAN FLX LAAC Device Gets CE Mark
by Zacks Equity Research
Receipt of the CE Mark followed by a limited launch of the WATCHMAN FLX device in Europe is likely to drive top-line contributions from Boston Scientific's (BSX) IC suite.
Boston Scientific (BSX) Up 1.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Boston Scientific Benefits From New Buyouts & Product Launch
by Zacks Equity Research
Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.
Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Eli Lilly (LLY) and U.S. Bancorp (USB).
Company News For Feb 7, 2019
by Zacks Equity Research
Companies In The News are: CPRI,BSX,GM,SNAP
Bright Near-Term Outlook for Medical Instruments Industry
by Zacks Equity Research
Growing medical awareness and economic prosperity have been enhancing the uptake of medical instruments in the emerging economies.
Boston Scientific (BSX) Beats on Q4 Earnings, Margins Dip
by Zacks Equity Research
Boston Scientific (BSX) is leaving no stone unturned to strengthen its core businesses and invest in global markets, which accounted for the uptick in sales across all geographies.
Boston Scientific (BSX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 5.41% and 0.11%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Can Boston Scientific (BSX) Q4 Earnings Fuel Overall Growth?
by Zacks Equity Research
We are hopeful that Boston Scientific (BSX) will report a strong IC business globally in Q4, backed by an innovative portfolio and robust commercial teams.
Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VREX vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
VREX vs. BSX: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Boston Scientific, Southern, BNY, Schlumberger and Southwest
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boston Scientific, Southern, BNY, Schlumberger and Southwest
Top Analyst Reports for Boston Scientific, Southern Company & BNY Mellon
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Boston Scientific (BSX), Southern Company (SO) and BNY Mellon (BK).
Boston Scientific Gains on Impressive Preliminary Q4 Results
by Zacks Equity Research
Boston Scientific's (BSX) solid top line is expected to be backed by growth across all segments and geographical regions in Q4.
Boston Scientific (BSX) to Buy Residual Shares of Millipede
by Zacks Equity Research
Boston Scientific's (BSX) buyout of the leftover stake in Millipede will integrate the latter's IRIS Transcatheter Annuloplasty Ring System in the Structural Heart portfolio of the former.
HRC or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRC vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Boston Scientific (BSX) closed at $37.67 in the latest trading session, marking a +1.7% move from the prior day.
HRC or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRC vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Boston Scientific (BSX) closed at $34.60 in the latest trading session, marking a +1.62% move from the prior day.
Boston Scientific's (BSX) $4.2B Buyout to Augment PI Business
by Zacks Equity Research
Boston Scientific (BSX) continues to expand on the back of its inorganic growth strategy. The latest takeover is expected to boost the PI business.
Edwards Lifesciences' CE Mark for SAPIEN 3 Boosts THVT Arm
by Zacks Equity Research
Latest CE Mark receipt is expected to fortify Edwards Lifesciences' (EW) position in Europe.